Recent data from the HERIZON-GEA-01 trial reveals striking efficacy metrics for zanidatamab in HER2-positive gastroesophageal adenocarcinoma. At 18 months, 56% of patients treated with zanidatamab plus chemotherapy remained progression-free compared to only 36% in the trastuzumab comparator arm—a meaningful 20-percentage-point difference. The hazard ratio of 0.56 reflects a statistically significant 44% reduction in disease progression or death risk. At the 12-month mark, the separation between treatment groups was similarly pronounced, with 65% progression-free survival for zanidatamab versus 49% for trastuzumab. These sustained survival advantages translate to extended median progression-free survival of 12.5 months with the novel bispecific antibody, compared to 8.5 months with standard therapy. The data underscore zanidatamab’s potential to reshape first-line treatment paradigms for this patient population.
Read the full article on GMJ Newsroom.
Was this article helpful?
